Patents by Inventor Dachun Liu

Dachun Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250084099
    Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 18, 2024
    Publication date: March 13, 2025
    Inventors: Daniel Tzvi Cohen, Jane Gong, Tarun Jain, Puneet Kumar, Dachun Liu, Anthony Mastracchio, Mark Mills, Andrew William Phillips, John K. Pratt, Sreenivas Punna, Jennifer Ann Stockwell, Le Wang, Yiyun Yu
  • Publication number: 20250075289
    Abstract: Provided is a method for preparing high-purity indium (In). The method for preparing the high-purity In includes: distilling refined In to obtain an In vapor-containing gas; and condensing the In vapor-containing gas to obtain the high-purity In; where the distilling is conducted at a temperature of 1,000° C. to 1,100° C. under a vacuum degree of 1.0×10?3 Pa to 5.0×10?2 Pa; and the condensing is conducted at a temperature of 700° C. to 900° C. under a vacuum degree of 1.0×10?3 Pa to 5.0×10?2 Pa. The In vapor-containing gas is obtained by controlling the temperature and vacuum degree of the distilling to evaporate In and impurities with a vapor pressure higher than the In. The temperature and vacuum degree of the condensing are adjusted to condense the In in the In vapor-containing gas.
    Type: Application
    Filed: August 15, 2024
    Publication date: March 6, 2025
    Inventors: Lingxin KONG, Jian PANG, Bin YANG, Baoqiang XU, Wenlong JIANG, Junjie XU, Dachun LIU, Yang TIAN, Yong DENG
  • Publication number: 20240375956
    Abstract: Disclosed is a method for removing impurity mercury from crude selenium. The method includes: mixing a vulcanizing agent with a crude selenium slag that is crushed to not more than 200 mesh uniformly, and performing briquetting to obtain a mixed material; adding the mixed material into a sealed furnace, and subjecting the mixed material to vulcanization by heating under an inert atmosphere to obtain a vulcanized selenium; subjecting the vulcanized selenium to primary vacuum distillation, such that selenium is converted into a gas phase and collected in a form of a volatile, and generated mercury sulfide and valuable elements are enriched in a resulting residue; and subjecting the selenium to secondary distillation to further remove mercury.
    Type: Application
    Filed: March 24, 2022
    Publication date: November 14, 2024
    Inventors: Baoqiang XU, Huan LUO, Bin YANG, Wenlong JIANG, Lang LIU, Guozheng ZHA, Heng XIONG, Yang TIAN, Lingxin KONG, Yifu LI, Fei WANG, Jia YANG, Tao QU, Dachun LIU
  • Publication number: 20240360124
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: November 21, 2023
    Publication date: October 31, 2024
    Applicant: AbbVie Inc.
    Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
  • Publication number: 20240328022
    Abstract: This invention presents an electrochemical metallurgical technique for extracting metals and sulfur from metal sulfides, offering an adjustable composition and mechanical properties during electrode preparation. The metal sulfide anode, submerged in an electrolyte with a cathode made of materials like titanium, copper, stainless steel, lead, zinc, aluminum or graphite, undergoes electrolysis. This process oxidizes sulfur in the metal sulfide to the anode and releases metal ions into the electrolyte, where they're reduced at the cathode. The method yields metal at the cathode and sulfur at the anode, with minimal environmental impact, low investment, and straightforward process.
    Type: Application
    Filed: June 14, 2024
    Publication date: October 3, 2024
    Inventors: Jia Yang, Kanwen Hou, baohong Wei, Jiancheng Qian, Baoqiang Xu, Bin Yang, Dachun Liu, Wenlong Jiang, Yong Deng, Yifu Li, Yang Tian, Heng Xiong, Fei Wang, Qingchun Yu, Hongwei Yang
  • Publication number: 20240287644
    Abstract: Provided is a recovery method for valuable metals in copper anode slime. By using the recovery method of the disclosure, selenium, copper, tellurium, arsenic, lead, bismuth, and precious metals gold and silver in the copper anode slime are recovered. The method adopts two-step vacuum carbothermal reduction to replace reduction smelting of anode slime and stepwise blowing of noble lead in the traditional pyrometallurgy, and avoids the emission of arsenic-containing soot in the traditional process. The recovered gold-rich residue contains almost no base metals such as lead, bismuth, antimony, and arsenic. After subjecting the gold-rich residue to leaching gold by chlorination and reduction, a gold powder could be obtained therefrom with a lower content of base metals than traditional processes. Therefore, the method greatly reduces the amount of produced slag, shortens the production cycle, and reduces the loss of precious metals in the slag.
    Type: Application
    Filed: October 12, 2022
    Publication date: August 29, 2024
    Inventors: Bin YANG, Baoqiang XU, Wenlong JIANG, Juhai DENG, Dachun LIU, Yang TIAN, Yifu LI, Lingxin KONG, Jia YANG
  • Publication number: 20240139809
    Abstract: An apparatus and method for preparing high-purity spherical magnesium and/or high-purity magnesium powder are provided. The apparatus includes a vertical furnace body, a heating zone, and a condensing zone, where a periphery of the condensing zone is provided with a first thermal insulation device and a second thermal insulation device sequentially from bottom to top, and each of the first thermal insulation device and the second thermal insulation device is removably arranged; the periphery of the condensing zone is further provided with a liquid cooling device; a gas inlet and a gas outlet are formed in the condensing zone; and an inner wall of the condensing zone is provided with an arrangement structure configured to arrange a collection device. A heating temperature of a material and condensation conditions in the condensing zone are controlled to make an evaporated magnesium vapor condensed on the collection device in the condensing zone.
    Type: Application
    Filed: January 11, 2024
    Publication date: May 2, 2024
    Applicant: KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Yang TIAN, Dong LIANG, Bin YANG, Baoqiang XU, Dachun LIU, Fei WANG, Yifu LI, Wenlong JIANG, Yong DENG, Jian WU, Lipeng WANG
  • Patent number: 11957717
    Abstract: The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: April 16, 2024
    Assignee: HRAIN BIOTECHNOLOGY CO., LTD.
    Inventors: Fei Huang, Tao Peng, Xuemei Zou, Pinglei Liu, Dachun Liu, Hui Huang
  • Publication number: 20230312601
    Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 30, 2023
    Publication date: October 5, 2023
    Inventors: Daniel Cohen, Jane Gong, Tarun Jain, Puneet Kumar, Dachun Liu, Anthony Mastracchio, Mark Mills, Andrew William Phillips, John K. Pratt, Sreenivas Punna, Jennifer Ann Stockwell, Le Wang, Yiyun Yu
  • Publication number: 20230285378
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: September 9, 2022
    Publication date: September 14, 2023
    Applicant: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Warren M. Kati, Tammie K. Jinkerson, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • Publication number: 20230241104
    Abstract: The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.
    Type: Application
    Filed: April 9, 2021
    Publication date: August 3, 2023
    Inventors: Fei HUANG, Tao PENG, Xuemei ZOU, Pinglei LIU, Dachun LIU, Hui HUANG
  • Publication number: 20230158039
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: June 30, 2022
    Publication date: May 25, 2023
    Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
  • Publication number: 20220017511
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: February 24, 2021
    Publication date: January 20, 2022
    Applicant: AbbVie Inc.
    Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
  • Publication number: 20210236508
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: August 18, 2020
    Publication date: August 5, 2021
    Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
  • Publication number: 20210130346
    Abstract: Compounds of formula (I), wherein R1, R2, R3, R5, R6, R7, A1, A2, A3, A4, X1, and X2 have any of the values defined in the specification and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS are provided. Pharmaceutical compositions comprising of compounds of formula (I) are also provided.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 6, 2021
    Applicant: AbbVie Inc.
    Inventors: David Hardee, Jason Brewer, Lisa Hasvold, Dachun Liu, Keith McDaniel, Michael Schrimpf, George Sheppard
  • Patent number: 10982299
    Abstract: A method for comprehensively processing noble lead provided and utilizes two instances of vacuum distillation to realize an open circuit of arsenic, lead, antimony and bismuth and the high-efficiency enrichment of precious metals of gold and silver, and can obtain elemental arsenic, a lead-bismuth-antimony alloy, a silver alloy and a copper alloy, respectively. The lead-bismuth-antimony alloy, the silver alloy and the copper alloy are processed by oxidation refining, electrorefining and chlorination refining to obtain refined lead, refined antimony, antimony trioxide, electrolytic silver and electrolytic copper, and to realize gold enrichment. The entire process has advantages of high metal direct yield, low energy consumption, short flow chart, simple equipment, etc., and vacuum distillation belongs to a physical process in which the alloy can be separated only by means of the difference in saturated vapor pressure between the metals, without generation of wastewater, waste gas and waste residue.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: April 20, 2021
    Assignees: Kunming University of Science and Technology, Kunming Dingbang Technology Co., Ltd.
    Inventors: Bin Yang, Dachun Liu, Wenlong Jiang, Guozheng Zha, Baoqiang Xu, Weiping Dai, Yifu Li, Qingchun Yu, Xiumin Chen, Hongwei Yang, Yang Tian, Yong Deng, Fei Wang, Heng Xiong, Jia Yang, Tao Qu, Lingxin Kong
  • Publication number: 20210070756
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: November 16, 2020
    Publication date: March 11, 2021
    Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • Publication number: 20210047304
    Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: May 26, 2020
    Publication date: February 18, 2021
    Inventors: Marlon Cowart, Steven Fidanze, Lisa Hasvold, Dachun Liu, Keith McDaniel, John Pratt, George Sheppard, Le Wang
  • Publication number: 20200291027
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: March 23, 2020
    Publication date: September 17, 2020
    Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • Publication number: 20200255426
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Applicant: AbbVie Inc.
    Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li